Loading...
01/10 19:06
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: limited cash balance raising sustainability doubts, a decision to not proceed with the India trial, and challenges in patient recruitment. Despite reduced expenses, the financial health is precarious. The Q&A section highlights uncertainties in trial outcomes and management's evasive responses, which further dampen sentiment. The combination of these factors suggests a negative outlook for the stock price.
Cash Balance As of September 30, 2025, the cash balance was approximately $5.8 million.
Consolidated Operating Expenses For the 3 months ended September 30, 2025, operating expenses were approximately $1.5 million, down by approximately $1.4 million or 48% year-over-year from $2.9 million in the same period of 2024. The decrease was due to reductions in payroll, general and administrative expenses, and professional fees.
Payroll and Related Expenses Decreased by approximately $778,000 year-over-year due to lower headcount, reduced bonus accruals, and absence of prior year severance charges.
General and Administrative Expenses Declined by approximately $437,000 year-over-year, driven by lower clinical trial costs, a $218,000 R&D tax incentive credit from the Australian government, and reductions in supplies, insurance, and other operational costs.
Professional Fees Decreased by approximately $177,000 year-over-year, mainly due to reduced investor relations and contract labor expenses, partially offset by higher legal, tax audit, and financial services costs.
Operating Loss Decreased to $1.5 million for the quarter, compared to $2.8 million in the prior year period, reflecting a reduction in expenses and alignment with strategic priorities.
Hemopurifier Oncology Trial: Progress in Australian oncology trial for Hemopurifier in patients with solid tumors unresponsive to anti-PD-1 agents. Cohort 1 completed with no device-related complications. Advancing to Cohort 2 with two treatments in a week. Safety and exploratory efficacy data being collected.
Long COVID Research: Presented preclinical data on Hemopurifier's potential for Long COVID treatment. Studying extracellular vesicles' role in Long COVID and preparing a manuscript for publication.
Simplified Hemopurifier System: Signed agreement to study compatibility of Hemopurifier with a simplified system for oncology units, potentially reducing operational complexity.
Clinical Trial Expansion: Efforts to accelerate enrollment in Australian oncology trial include virtual investigator meetings, adding new sites, and clinical trial advertising.
Cost Reductions: Operating expenses reduced by 48% YoY to $1.5M due to lower headcount, reduced bonuses, and Australian R&D tax incentives.
Resource Alignment: Operating loss reduced to $1.5M from $2.8M YoY, reflecting alignment of resources with strategic priorities.
Australian Oncology Trial Enrollment: Challenges in accelerating participant enrollment for the Hemopurifier trial, requiring a multi-pronged strategy including virtual meetings, additional site identification, and clinical trial advertising.
Regulatory Approval Process: The need for extensive safety and efficacy trials, including a premarket approval study (PMA), to meet FDA and other regulatory requirements, which could delay product commercialization.
Long COVID Research: No approved treatment for Long COVID exists, and while the Hemopurifier shows potential, further research and validation are required, posing a challenge to market entry.
Operational Complexity: Current Hemopurifier operation requires a large double-lumen dialysis catheter, a complex dialysis machine, and specialized staff, limiting its usability in oncology units.
Financial Sustainability: Limited cash balance of $5.8 million as of September 30, 2025, with ongoing operating expenses, raising concerns about long-term financial sustainability.
Australian oncology trial: The trial is advancing to the second cohort where participants will receive two Hemopurifier treatments during a 1-week treatment period. Efforts are being made to accelerate enrollment through virtual investigator meetings, adding new sites, and clinical trial advertising. The trial aims to determine the safety and efficacy of Hemopurifier treatments, with exploratory analyses to inform future efficacy and safety trials, including a premarket approval study required by the FDA and other regulatory agencies.
Preclinical R&D activities: Aethlon Medical is studying the cargo of extracellular vesicles removed from Long COVID patient samples and preparing a manuscript for publication. The company has signed a material transfer agreement to explore a simplified system for Hemopurifier treatments, which could enable treatments in oncology units in the future.
The selected topic was not discussed during the call.
The earnings call reveals several concerns: limited cash balance raising sustainability doubts, a decision to not proceed with the India trial, and challenges in patient recruitment. Despite reduced expenses, the financial health is precarious. The Q&A section highlights uncertainties in trial outcomes and management's evasive responses, which further dampen sentiment. The combination of these factors suggests a negative outlook for the stock price.
The earnings call highlights several risks and challenges, including regulatory delays, financial constraints, and clinical trial uncertainties. Despite positive preclinical data and cost-saving measures, the company's limited cash balance and operational risks overshadow potential benefits. The Q&A section revealed management's hesitance to provide clear guidance on trial timelines and efficacy, further dampening investor sentiment. The decision to halt the India trial due to regulatory issues adds to the negative outlook. Overall, these factors suggest a negative stock price reaction in the short term.
The earnings call summary shows reduced operating expenses and a maintained cash balance, which are positive. However, the noncash charge and reliance on equity financing are concerns. The Q&A section reveals no significant capital outlay for collaborations and faster patient enrollment, but vague responses on funding and partnerships raise uncertainty. The overall sentiment is neutral due to mixed financial health and unclear future funding plans.
The earnings call summary reveals a mixed picture, with cost reductions and tax rebates being positive, but offset by significant risks like regulatory challenges, supply chain issues, and patient enrollment difficulties. The Q&A section shows management's vague responses, especially on patient enrollment timelines and Hemopurifier's potential, raising concerns. Despite expense reductions, increasing G&A expenses and operational risks as trials progress are worrying. These factors, combined with the lack of clear guidance, suggest a negative stock reaction in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
